Olema Pharmaceuticals, Inc.
OLMA
$4.42
$0.163.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -129.47M | -122.68M | -109.63M | -99.34M | -96.66M |
| Total Depreciation and Amortization | 393.00K | 365.00K | 360.00K | 365.00K | 377.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.57M | 12.98M | 12.31M | 11.89M | 13.14M |
| Change in Net Operating Assets | 9.16M | 12.79M | 4.68M | 248.00K | -589.00K |
| Cash from Operations | -104.35M | -96.54M | -92.27M | -86.83M | -83.73M |
| Capital Expenditure | -159.00K | -159.00K | -159.00K | -153.00K | -- |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 14.00K | 14.00K | 14.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -93.37M | -9.86M | -81.23M | -62.24M | -4.87M |
| Cash from Investing | -93.53M | -10.02M | -81.37M | -62.38M | -4.85M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 275.48M | 24.97M | 155.74M | 142.18M | 133.42M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.66M | 74.00K | -166.00K | -167.00K | 0.00 |
| Cash from Financing | 268.82M | 25.04M | 155.58M | 142.02M | 133.42M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.94M | -81.52M | -18.07M | -7.20M | 44.84M |